Previous investigations on the mutual pharmacokinetic influence of L-dopa and @entity935 agonists in @entity191 ( @entity191 ) have shown controversial results. Two studies of the possible clinical and pharmacokinetic interaction between L-dopa and @entity9229 were performed in 10 @entity1 with de novo @entity191 and 12 @entity1 with fluctuating @entity191 . In the first study (de novo @entity1 ), @entity9229 was administered at increasing dosages until the maximum dosage of 2 mg/day once a day for 8 weeks; subsequently L-dopa (250 mg/day) was added. Blood levels of @entity9229 were assayed in two different days, before starting @entity5022 week thereafter. In the second 8-week study (fluctuating @entity1 ), @entity9229 was added to the current L-dopa therapy (maximum dosage 4 mg/day once a day). Blood levels of L-dopa were measured in two different days, before @entity9229 was added, and at the end of the study. In both studies motor performance was evaluated by means of the Unified @entity191 Rating Scale (motor examination) and the Clinical Global Impression Scale; on-off diaries of daily motor condition also were filled by fluctuating @entity1 . In @entity1 with de novo @entity191 , @entity9229 pharmacokinetic parameters were unmodified by the adjunct of L-dopa, except that the time to reach the peak concentration (Tmax) significantly increased after L-dopa. In @entity1 with fluctuating @entity191 , no modification of L-dopa pharmacokinetics was observed before and after @entity9229 coadministration. Clinical evaluations confirmed that @entity9229 is effective in the treatment of advanced @entity191 as well as in the management of de novo @entity1 .

Clinical and pharmacokinetic evaluation of L-dopa and XXXX cotreatment in @entity191 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity9229 :: ('MESH:C047047', 'Chemical') :: ['cabergoline'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity5022 :: ('28938', 'Gene') :: ['L-dopa, and 1'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", "Parkinson's Disease", 'PD']
@entity9229 :: (MESH:C047047,Chemical) :: ['cabergoline']
